It was in 2003 that Scott M. Rocklage, Ph.D. first joined 5AM Ventures. He joined the company as a Venture Partner and was named a Managing Partner just a year later. Scott M. Rocklage has been in the pharmaceutical industry for more than 30 years and has developed a career that involves research and development, corporate management and venture capitalism.
Before joining 5AM Ventures, Dr. Scott Rocklage had served as an executive at a number of companies. He is the former president and Chief Executive Officer or Nycomed Salutar. He has also served as the Chairman of the Board and CEO of Cubist Pharmaceuticals. He serves a board member for a number of pharmaceutical companies that have been invested in by 5AM Ventures including Rennovia, Cidara, and Kinestral. He has also served as chairman for a number of companies that have been successfully acquired including Miikana, Ilypsa, and Semprus.
Dr. Scott Rocklage earned his degree in chemistry from the University and California, Berkeley. He then attended MIT where he earned his Ph.D. in Chemistry. While at MIT, his Professor Richard R. Schrock went on to earn the Nobel Prize in Chemistry. Since graduation, Dr. Rocklage has been credited with being the inventor or co-inventor of 30 U.S. patents. He has also published more than 100 peer-reviewed research papers. Three of his medical products have received FDA approval; Teslascan, Omniscan, and Cubicin and learn more about Scott.
One of the areas of research that Dr. Rocklage finds particularly promising is targeting specific mutations in order to cure cancer. This innovative technique has already saved lives and is showing a lot of promise in the near future. He has also stated that he works with many entrepreneurs that are developing medicines to treat other diseases that haven’t been addressed yet and read full article.
As an entrepreneur, Dr. Rocklage believes it is important to take measured risks. He said he thinks many people should control their own future by becoming entrepreneurs rather than stay at Fortune 500 companies where others control them and their futures. He has also said that as an entrepreneur he learned that if he hires the wrong person it’s important to quickly replace them rather than hold out false hope for improvements and contact him.